Tiến triển trung hạn của tăng áp lực động mạch phổi ở trẻ đẻ non mắc loạn sản phế quản phổi=Medium-term progress of pulmonary hypertension in bronchopulmonary dysplasia

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Hải Vân Đặng, Hữu Nhật Nguyễn, Thị Hải Anh Nguyễn, Minh Điển Trần

Ngôn ngữ: vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Nghiên cứu y học (Đại học Y Hà Nội), 2024

Mô tả vật lý: tr.10-18

Bộ sưu tập: Metadata

ID: 244696

Thêm vào giỏ

Pulmonary hypertension (PH) is a common cardiovascular complication in bronchopulmonary dysplasia (BPD), with deterioration in the neonatal period leading to subsequent hospitalizations. The study aimed to evaluate the progression of pulmonary hypertension in infants with bronchopulmonary dysplasia in the first 12 months of life. This was a case series conducted at the Vietnam National Children's Hospital from January 2022 to April 2024. 44 patients with PH - BPD were enrolled in the study, and the 12-month mortality rate was 40.91%
6-month mortality was 34,09%. All deceased patients still had PH with a higher rate of mechanical ventilation up to 28 days of life, more severe BPD, severe PH, pneumonia, and HFO mechanical ventilation than the surviving patients. The rate of treatment with Sildenafil was 52.27%, the combination of Sildenafil and Bosentan was 13.64%, and the combination of Sildenafil and Iloprost was 13.64%. The rate of recovery from PH at 3 months, 6 months, and 12 months was 15.91%
44.19%
52.50%
respectively. PH-BPD has a high mortality rate in the first 6 months, but patients who survive have a high chance of completely recovering from PH in the first 12 months of life.Tăng áp lực mạch phổi (TAP) là biến chứng tim mạch phổ biến ở trẻ đẻ non loạn sản phế quản phổi (LSPQP), thường đi kèm với kết cục xấu trong giai đoạn sơ sinh và các đợt tái nhập viện. Nghiên cứu nhằm đánh giá tiến triển của tăng áp lực mạch phổi ở trẻ loạn sản phế quản phổi trong 12 tháng đầu. Đây là nghiên cứu loạt ca bệnh được thực hiện tại Bệnh viện Nhi Trung ương từ tháng 01/2022 đến tháng 04/2024. Có 44 bệnh nhân LSPQP - TAP được chọn vào nghiên cứu, 18/44 bệnh nhân (40,91%) tử vong trong 12 tháng, chủ yếu tử vong trong 6 tháng đầu (34,09%). Tất cả các bệnh nhân tử vong đều còn tình trạng TAP. Nhóm bệnh nhân tử vong có tỷ lệ cao hơn về thở máy đến 28 ngày đầu đời, LSPQP nặng, TAP nặng, viêm phổi, thở máy HFO so với nhóm bệnh nhân sống. Tỷ lệ điều trị thuốc Sildenafil là 54,55%, phối hợp Sildenafil và Bosentan là 15.91%, phối hợp Sildenafil và Iloprost là 13,64%. Tỷ lệ khỏi TAP tại thời điểm 3 tháng, 6 tháng, 12 tháng tương ứng là 13,64%
40,91%
50,00%. Như vậy, trẻ LSPQP - TAP có tỷ lệ tử vong cao trong 6 tháng đầu nhưng bệnh nhân sống có khả năng cao khỏi hoàn toàn TAP trong 12 tháng đầu đời.

1. Đọc trực tuyến

1. Đọc trực tuyến

Tạo bộ sưu tập với mã QR